abstract |
The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor. The present invention is directed, in part, to compounds comprising a conjugated complement cascade inhibitor. The compounds may advantageously bind to a receptor in a component of the complement cascade, and may thereby inhibit the complement cascade or inhibit the effects of the proteins which are formed from the cascade (for example C3a and C5a). In one embodiment, the present invention provides a pharmaceutical for treating a patient, comprising a conjugated complement inhibitor. In another embodiment, the present invention provides a method of treating a patient to suppress activation of the complement cascade, comprising administering a conjugated complement inhibitor to the patient. These and other aspects of the invention will become more apparent from the present description and claims. |